API | bivatuzumab mertansine

bivatuzumab mertansine Report issue

Biologics mAb ADC Experimental

AACT ChEMBL MeSH

Active Ingredient History

NOW

Bivatuzumab mertansine is a combination of bivatuzumab, a humanized monoclonal antibody, and mertansine, a cytotoxic agent. It is designed for the treatment of squamous cell carcinoma. ^Wikipedia

Chemistry

SMILES: Missing data
InChIKey: Missing data
Mol. Mass: Missing data
ALogP: Missing data
ChEMBL Molecule:
bivatuzumab mertansine

More Chemistry

Pharmacology

Mechanisms of Action:
- CD44 antigen (Homo sapiens) ^UniProt
Multi-specific: No
Payload: maytansinoid
Black Box: No
Availability: Missing data
Delivery Methods: Missing data
Pro Drug: No

bivatuzumab mertansine | biwa-1-dm1 | biwi 1 compound

Organizations (1)

Research & Development (1)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Marketing (0)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Indications (3)

Approved Indications (0)

Experimental Indications - Clinical Trial Phases 1-4 (3)

Breast Neoplasms (Phase 1)

Carcinoma, Squamous Cell (Phase 1)

Head and Neck Neoplasms (Phase 1)

Overview

Highest Phase: Phase 1
# of Trials: 4
# of Trial Organizations: 1

Trials by Phase

Trial	Phase	Start Date	Organizations	Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue